CN114082000B - Biodegradable drug-loaded high polymer material stent and preparation method thereof - Google Patents
Biodegradable drug-loaded high polymer material stent and preparation method thereof Download PDFInfo
- Publication number
- CN114082000B CN114082000B CN202111491298.7A CN202111491298A CN114082000B CN 114082000 B CN114082000 B CN 114082000B CN 202111491298 A CN202111491298 A CN 202111491298A CN 114082000 B CN114082000 B CN 114082000B
- Authority
- CN
- China
- Prior art keywords
- high polymer
- polymer material
- parts
- drug
- loaded high
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/028—Other inorganic materials not covered by A61L31/022 - A61L31/026
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a biodegradable drug-loaded high polymer material stent and a preparation method thereof, belonging to the technical field of high polymer materials. The biodegradable drug-loaded high polymer material stent comprises the following raw materials: chitin, calcium phosphate, polyacrylic resin, vinyl pyrrolidone, compound amino acid, chondroitin sulfate, and therapeutic drugs; the preparation method comprises the following steps: firstly, preparing a net-shaped structure bracket, then spraying the therapeutic drug on the net-shaped structure bracket after ultrasonic atomization, thereby obtaining the biodegradable drug-loaded high polymer material bracket. The biodegradable drug-loaded high polymer material stent has the tensile strength of 72.5MPa and the bending strength of 25MPa, and shows good mechanical properties; in vitro cytotoxicity tests are all grade 1, which shows that the method has small influence on cell activity, shows excellent cell compatibility and has important application value.
Description
Technical Field
The invention relates to the technical field of high polymer materials, in particular to a biodegradable drug-loaded high polymer material stent and a preparation method thereof.
Background
The stent is a means for keeping the lumen of a human body unobstructed in the field of interventional therapy. It is typically delivered to the site of the lesion through the body's vasculature for dilation to maintain patency of the vessel after dilation. The most widely used and most successful surgical Percutaneous Transluminal Coronary Angioplasty (PTCA) is implemented as follows: the stent pre-loaded on the saccule is conveyed to a lesion part through a pre-placed guide catheter and a guide wire, then the saccule is pressurized to expand the stent, the stent is expanded to open the lesion part and is left, and then the saccule is withdrawn.
At present, the stents used in large numbers are metal stents, which have been found to cause unintended late thrombosis if they are in contact with blood for a long time, and the mechanical action on the blood vessel wall deteriorates the elasticity of the blood vessel with consequent rupture or aneurysm formation of the blood vessel, and the long-term presence of the stent can also cause proliferation of the surrounding tissue, re-occluding the lumen. Biodegradable or bioabsorbable stent can solve the above problems well, but the mechanical property of biodegradable stent is poorer than that of metal stent body, so how to prepare biodegradable drug-loaded high molecular material stent with good biocompatibility and excellent mechanical property is a technical problem to be solved urgently at present.
Disclosure of Invention
The invention aims to provide a biodegradable drug-loaded high polymer material scaffold and a preparation method thereof.
In order to achieve the purpose, the invention provides the following scheme:
one purpose of the invention is to provide a biodegradable drug-loaded high polymer material stent, which comprises the following raw materials in parts by weight: 12-18 parts of chitin, 6-12 parts of calcium phosphate, 15-20 parts of polyacrylic resin, 12-18 parts of vinyl pyrrolidone, 17-22 parts of compound amino acid, 5-10 parts of chondroitin sulfate and 5-10 parts of therapeutic drugs.
Further, the complex amino acids include valine, leucine, and methionine.
Furthermore, the mass ratio of valine to leucine to methionine is (5-8) to (3-6) to (5-7).
Further, the therapeutic drug is any one of anti-inflammatory drugs, antibiotics, anti-tumor drugs and nano silver.
Further, the anti-inflammatory agent can be cortisone, aspirin, analgin, acetaminophen, indomethacin, piroxicam, ketorolac, etc.; the antibiotic can be penicillin, erythromycin, azithromycin and the like; the antineoplastic agent can be dactinomycin, daunorubicin, paclitaxel derivatives, pentafluorouracil, rapamycin, etc.
The invention also provides a preparation method of the biodegradable drug-loaded high polymer material stent, which comprises the following steps:
(1) mixing and stirring chitin, calcium phosphate and polyacrylic resin, sequentially adding deionized water, vinyl pyrrolidone, compound amino acid and chondroitin sulfate, performing melting treatment, and injecting into a mold for molding to obtain a net-structure support;
(2) mixing therapeutic drugs with deionized water, and spraying the mixture on the net-shaped structure stent after ultrasonic atomization to obtain the biodegradable drug-loaded high polymer material stent.
Further, in the step (1), the rotation speed of the mixing and stirring is 80-100 r/min, and the time is 30-60 min; the dosage of the deionized water is 1-2 times of the total weight of the chitin, the calcium phosphate and the polyacrylic resin.
Further, in the step (1), the temperature of the melting treatment is 120-150 ℃ and the time is 20-30 min.
Further, in the step (1), the diameter of the net-shaped structure support is 10-15 mm, and the wall thickness is 0.1-1 mm.
Further, in the step (2), the dosage of the deionized water is 1-1.5 times of the mass of the therapeutic drug.
The invention has the following technical effects:
The invention provides a biodegradable drug-loaded high polymer material stent, wherein chitin is a polysaccharide substance extracted from shells of marine crustaceans, can accelerate wound healing of human bodies, and has the advantages of no biotoxicity, low price, good mechanical strength and the like, and good biocompatibility. The calcium phosphate provides trace phosphorus element and calcium element, and is helpful for improving the biocompatibility of the stent. The compound amino acid is formed by mixing valine, leucine and methionine according to a certain proportion, and can promote the normal growth of a body, repair tissues and regulate blood sugar; chondroitin sulfate has the effect of promoting cartilage regeneration, and can further improve biocompatibility.
The invention reasonably selects chitin, calcium phosphate, polyacrylic resin, vinyl pyrrolidone, compound amino acid and chondroitin sulfate to prepare the stent with the reticular structure, and loads therapeutic drugs to obtain the biodegradable drug-loaded high polymer material stent, wherein the tensile strength of the biodegradable drug-loaded high polymer material stent can reach 72.5MPa, the bending strength of the biodegradable drug-loaded high polymer material stent can reach 25MPa, and the mechanical property is good; in vitro cytotoxicity tests are all grade 1, which shows that the method has small influence on cell activity, shows excellent cell compatibility and has wide application value.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The description and examples are intended to be illustrative only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
In the invention, all raw materials are conventional commercial products.
Example 1
(1) Mixing and stirring 16 parts of chitin, 8 parts of calcium phosphate and 18 parts of polyacrylic resin at the rotating speed of 90r/min for 45 min;
(2) sequentially adding deionized water (the dosage is 1.5 times of the total weight of the chitin, the calcium phosphate and the polyacrylic resin), 15 parts of vinyl pyrrolidone, 20 parts of compound amino acid (the mass ratio of valine to leucine to methionine is 7:5:6) and 7 parts of chondroitin sulfate, then carrying out melting treatment at the temperature of 130 ℃ for 25min, injecting into a mold for molding, and obtaining a net-structure support with the diameter of 12mm and the wall thickness of 0.5 mm;
(3) 8 parts of aspirin and deionized water are mixed, the using amount of the deionized water is 1 time of the mass of the aspirin, and the mixture is sprayed on the mesh-structure stent after ultrasonic atomization, so that the biodegradable drug-loaded high polymer material stent is obtained.
Example 2
(1) Mixing and stirring 12 parts of chitin, 6 parts of calcium phosphate and 15 parts of polyacrylic resin at the rotating speed of 80r/min for 60 min;
(2) sequentially adding deionized water (the dosage is 1 time of the total weight of the chitin, the calcium phosphate and the polyacrylic resin), 12 parts of vinyl pyrrolidone, 17 parts of compound amino acid (the mass ratio of valine to leucine to methionine is 5:3:5) and 5 parts of chondroitin sulfate, then carrying out melting treatment at 120 ℃ for 30min, injecting into a mold for molding, and obtaining a net-structure support with the diameter of 10mm and the wall thickness of 0.1 mm;
(3) mixing 5 parts of penicillin with deionized water, wherein the using amount of the deionized water is 1 time of the mass of the penicillin, and spraying the mixture on the net-shaped structure stent after ultrasonic atomization to obtain the biodegradable drug-loaded high polymer material stent.
Example 3
(1) Mixing 18 parts of chitin, 12 parts of calcium phosphate and 20 parts of polyacrylic resin, and stirring at the rotation speed of 100r/min for 30 min;
(2) Sequentially adding deionized water (the dosage is 2 times of the total weight of the chitin, the calcium phosphate and the polyacrylic resin), 18 parts of vinyl pyrrolidone, 22 parts of compound amino acid (the mass ratio of valine to leucine to methionine is 8:6:7) and 10 parts of chondroitin sulfate, then carrying out melting treatment at the temperature of 150 ℃ for 20min, injecting into a mold for molding, and obtaining a net-structure support with the diameter of 15mm and the wall thickness of 1 mm;
(3) mixing 10 parts of paclitaxel with deionized water, wherein the dosage of the deionized water is 1.5 times of the mass of the paclitaxel, and spraying the mixture on the mesh-structure stent after ultrasonic atomization to obtain the biodegradable drug-loaded high polymer material stent.
Comparative example 1
The difference from example 1 is that 12 parts of chitin was reduced to 5 parts.
Comparative example 2
The difference from example 1 is that no calcium phosphate is added.
Comparative example 3
The difference from example 1 is that no vinylpyrrolidone is added.
Comparative example 4
The difference from example 1 is that leucine and methionine are not added.
Comparative example 5
The difference from example 1 is that chondroitin sulfate is not added.
Effect verification
And (3) carrying out performance detection on the biodegradable drug-loaded high polymer material scaffolds of each example and comparative example. And (3) testing tensile strength: the instrument is an INSTRON-1121 type material testing machine, the detection condition is F multiplied by S is 5KN, and the stretching speed is 10 mm/min; and (3) testing the bending strength: the apparatus is a WDWGN-20kN biological material torsion testing machine, and the bending speed is 10 mm/min; in vitro cytotoxicity tests were carried out according to GB/T16886.5-2003 and the results are shown in Table 1.
TABLE 1
As can be seen from Table 1, the biodegradable drug-loaded polymer material scaffold of the invention has tensile strength of 72.5MPa and bending strength of 25MPa, which indicates good mechanical properties; in vitro cytotoxicity tests are all grade 1, which shows that the method has small influence on cell activity, shows excellent cell compatibility and has important application value in the field of medical treatment.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (5)
1. A biodegradable drug-loaded high polymer material stent is characterized by comprising the following raw materials in parts by weight: 12-18 parts of chitin, 6-12 parts of calcium phosphate, 15-20 parts of polyacrylic resin, 12-18 parts of vinyl pyrrolidone, 17-22 parts of compound amino acid, 5-10 parts of chondroitin sulfate and 5-10 parts of therapeutic drugs;
the complex amino acids include valine, leucine, and methionine;
the mass ratio of valine to leucine to methionine is (5-8) to (3-6) to (5-7);
The therapeutic drug is one of anti-inflammatory drug, antibiotic, antineoplastic drug and nano silver;
the preparation method of the biodegradable drug-loaded high polymer material stent comprises the following steps:
(1) mixing and stirring chitin, calcium phosphate and polyacrylic resin, sequentially adding deionized water, vinyl pyrrolidone, compound amino acid and chondroitin sulfate, performing melting treatment, and injecting into a mold for molding to obtain a net-structure support;
(2) mixing a therapeutic drug with deionized water, and spraying the mixture on the mesh-structure stent after ultrasonic atomization to obtain the biodegradable drug-loaded high polymer material stent.
2. The biodegradable drug-loaded high polymer material stent of claim 1, wherein in the step (1), the rotation speed of mixing and stirring is 80-100 r/min, and the time is 30-60 min; the dosage of the deionized water is 1-2 times of the total weight of the chitin, the calcium phosphate and the polyacrylic resin.
3. The biodegradable drug-loaded high polymer material stent of claim 1, wherein in the step (1), the temperature of the melting treatment is 120-150 ℃ and the time is 20-30 min.
4. The biodegradable drug-loaded high polymer material stent of claim 1, wherein in the step (1), the diameter of the mesh-structured stent is 10-15 mm, and the wall thickness is 0.1-1 mm.
5. The biodegradable drug-loaded high polymer material stent of claim 1, wherein in the step (2), the dosage of the deionized water is 1-1.5 times of the mass of the therapeutic drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111491298.7A CN114082000B (en) | 2021-12-08 | 2021-12-08 | Biodegradable drug-loaded high polymer material stent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111491298.7A CN114082000B (en) | 2021-12-08 | 2021-12-08 | Biodegradable drug-loaded high polymer material stent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114082000A CN114082000A (en) | 2022-02-25 |
| CN114082000B true CN114082000B (en) | 2022-07-29 |
Family
ID=80306889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111491298.7A Active CN114082000B (en) | 2021-12-08 | 2021-12-08 | Biodegradable drug-loaded high polymer material stent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114082000B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1470247A (en) * | 2002-07-24 | 2004-01-28 | 清华大学 | Bone repairing material |
| CN101234217A (en) * | 2008-03-07 | 2008-08-06 | 北京蓝景创新科技有限公司 | Functional targeting therapeutic degradable biological bracket |
| CN101678041A (en) * | 2007-03-30 | 2010-03-24 | 梅迪沃什有限公司 | Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use |
| CN101947333A (en) * | 2010-08-27 | 2011-01-19 | 安泰科技股份有限公司 | Biodegradable medicament-loaded polymer scaffold and preparation method thereof |
| WO2019077348A1 (en) * | 2017-10-18 | 2019-04-25 | The University Of Nottingham | Porous material |
| CN110078943A (en) * | 2019-05-09 | 2019-08-02 | 南京林业大学 | Nanometer chitin composite hydrogel, preparation method and the composite material of stratiform mineralising |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103200971B (en) * | 2010-08-30 | 2015-09-30 | 哈佛大学校长及研究员协会 | Complex layered materials, its manufacture method and application thereof |
-
2021
- 2021-12-08 CN CN202111491298.7A patent/CN114082000B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1470247A (en) * | 2002-07-24 | 2004-01-28 | 清华大学 | Bone repairing material |
| CN101678041A (en) * | 2007-03-30 | 2010-03-24 | 梅迪沃什有限公司 | Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use |
| CN101234217A (en) * | 2008-03-07 | 2008-08-06 | 北京蓝景创新科技有限公司 | Functional targeting therapeutic degradable biological bracket |
| CN101947333A (en) * | 2010-08-27 | 2011-01-19 | 安泰科技股份有限公司 | Biodegradable medicament-loaded polymer scaffold and preparation method thereof |
| WO2019077348A1 (en) * | 2017-10-18 | 2019-04-25 | The University Of Nottingham | Porous material |
| CN110078943A (en) * | 2019-05-09 | 2019-08-02 | 南京林业大学 | Nanometer chitin composite hydrogel, preparation method and the composite material of stratiform mineralising |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114082000A (en) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2476726B1 (en) | Processing of chitosan and chitosan derivatives | |
| JP6857214B2 (en) | Sustained release composition for injection and its use for treating joint inflammation and associated pain | |
| US20210128795A1 (en) | Spiral coated stent with controllable gradient degradation, preparation method thereof and application thereof | |
| EP2614828B1 (en) | Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material | |
| CN109503797A (en) | A kind of medical degradable polyurethane and application thereof with antibacterial activity | |
| US20070190103A1 (en) | Implantable medical device with surface-eroding polyester drug delivery coating | |
| WO2019076178A1 (en) | Degradation time controllable and breaking elongation adjustable medical degradable polyurethane | |
| WO2017054433A1 (en) | Elastic modulus adjustable polyurethane composition, scaffold composite and preparation method thereof | |
| EP1501565A1 (en) | Compounds and method for coating surfaces in a haemocompatible manner | |
| CN103356510A (en) | Methods for producing drug-containing bioabsorbable fibers | |
| WO2004000382A1 (en) | Silicone blends and composites for drug delivery | |
| US20100279952A1 (en) | Cross-linked hydrogel containing an active substance | |
| Wang et al. | 3D printing of multi-functional artificial conduits against acute thrombosis and clinical infection | |
| Ilomuanya | Hydrogels as biodegradable biopolymer formulations | |
| CN114082000B (en) | Biodegradable drug-loaded high polymer material stent and preparation method thereof | |
| WO2020087896A1 (en) | Medical degradable polyurethane having antibacterial activity and application thereof | |
| KR102103180B1 (en) | Anti-adhesion Composition Including Hyaluronic Acid Derivative, Pullulan and Carboxymethyl Cellulose and Manufacturing Method Thereof | |
| EP2146755B1 (en) | Device made at least partially of n-acetylchitosan with controlled biodissolution | |
| CN108577916B (en) | Preparation method of anastomat for gastrointestinal surgery | |
| KR101626220B1 (en) | Film-type anti-adhesion membranes comprising silk fibroin and preparing method thereof | |
| CN1416918A (en) | Medicine conveyance through conformal film | |
| WO2009057174A1 (en) | Intracorporeal medical device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |